What is Viking Therapeutics Inc's earnings per share (EPS)?

Viking Therapeutics Inc (VKTX) reported diluted earnings per share of $-3.19 for fiscal year 2025. This represents a -215.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Viking Therapeutics Inc Financials

VKTX

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Viking Therapeutics Inc (VKTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI VKTX FY2025 2026-04-30

A cash-consuming development model is being funded by equity capital and investment inflows rather than operations.

Between FY2024 and FY2025, R&D spending jumped from $101.6M to $345.0M, which is the clearest reason the loss profile steepened so abruptly while corporate overhead barely moved. At the same time, operating cash burn remained below the net loss, showing that the accounting loss was not a one-for-one cash drain and that liquidity was being managed through investing inflows and earlier capital raising instead of business self-funding.

The FY2025 cost mix shows where management is placing its bets: SG&A stayed near $48.4M while R&D reached $345.0M. That pattern looks less like overhead sprawl and more like a deliberate expansion of programs, which matters because the burn is tied mainly to development activity rather than fixed corporate infrastructure.

Even after the heavier burn, FY2025 ended with cash of $165.8M against total liabilities of $76.7M. With no long-term debt reported and share count higher than FY2023, the balance sheet indicates a company that has preserved solvency by leaning on equity funding, so financing pressure shows up more through dilution than through leverage.

Financial Health Signals

Financial Profile 33/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Viking Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

100

Viking Therapeutics Inc carries a low D/E ratio of 0.12, meaning only $0.12 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 9.33, Viking Therapeutics Inc holds $9.33 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Returns

Viking Therapeutics Inc generates a -56.3% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -12.5% the prior year.

Piotroski F-Score Weak

1/9

Viking Therapeutics Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality Low Quality

0.77x

For every $1 of reported earnings, Viking Therapeutics Inc generates $0.77 in operating cash flow (-$278.7M OCF vs -$359.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

Viking Therapeutics Inc generated $0 in revenue in fiscal year 2025.

EBITDA

N/A

Net Income

-$359.6M

YoY-227.1%

Viking Therapeutics Inc reported -$359.6M in net income in fiscal year 2025. This represents a decrease of 227.1% from the prior year.

EPS (Diluted)

$-3.19

YoY-215.8%

Viking Therapeutics Inc earned $-3.19 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 215.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$165.8M

YoY+521.6%

5Y CAGR+41.6%

10Y CAGR+71.2%

Viking Therapeutics Inc held $165.8M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

116M

YoY+2.9%

5Y CAGR+9.3%

10Y CAGR+28.1%

Viking Therapeutics Inc had 116M shares outstanding in fiscal year 2025. This represents an increase of 2.9% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-56.3%

YoY-43.8pp

5Y CAGR-40.1pp

10Y CAGR+212.0pp

Viking Therapeutics Inc's ROE was -56.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 43.8 percentage points from the prior year.

Capital Allocation

R&D Spending

$345.0M

YoY+239.4%

5Y CAGR+61.0%

10Y CAGR+47.7%

Viking Therapeutics Inc invested $345.0M in research and development in fiscal year 2025. This represents an increase of 239.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

VKTX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$0	$0	$0	$0	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$345.0M+239.4%	$101.6M+59.3%	$63.8M+17.6%	$54.2M+20.6%	$45.0M+40.9%	$31.9M
SG&A Expenses	$48.4M-1.8%	$49.3M+33.1%	$37.0M+129.6%	$16.1M+50.6%	$10.7M-0.3%	$10.7M
Operating Income	-$393.3M-160.6%	-$150.9M-49.7%	-$100.8M-43.3%	-$70.4M-26.4%	-$55.7M-30.5%	-$42.7M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$1K0.0%	$1K0.0%	$1K0.0%	$1K-50.0%	$2K	$0
Net Income	-$359.6M-227.1%	-$110.0M-28.0%	-$85.9M-24.7%	-$68.9M-25.2%	-$55.0M-39.2%	-$39.5M
EPS (Diluted)	$-3.19-215.8%	$-1.01-11.0%	$-0.91-1.1%	$-0.90-26.8%	$-0.71	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$0	N/A	$0	$0	$0	N/A	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$150.2M	N/A	$90.0M+49.5%	$60.2M+45.3%	$41.4M	N/A	$22.8M-4.1%	$23.8M
SG&A Expenses	$14.0M	N/A	$8.6M-40.3%	$14.4M+2.4%	$14.1M	N/A	$13.8M+33.9%	$10.3M
Operating Income	-$164.1M	N/A	-$98.6M-32.2%	-$74.6M-34.4%	-$55.5M	N/A	-$36.6M-7.3%	-$34.1M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$158.3M	N/A	-$90.8M-38.5%	-$65.6M-43.7%	-$45.6M	N/A	-$24.9M-12.1%	-$22.3M
EPS (Diluted)	$-1.37	N/A	$-0.81-39.7%	$-0.58-41.5%	$-0.41	N/A	$-0.22-10.0%	$-0.20

VKTX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$715.7M-21.2%	$908.3M+146.5%	$368.5M+118.7%	$168.5M-20.0%	$210.7M-17.9%	$256.5M
Current Assets	$715.6M-21.1%	$907.2M+147.0%	$367.2M+119.8%	$167.0M-20.7%	$210.5M-17.8%	$256.1M
Cash & Equivalents	$165.8M+521.6%	$26.7M-51.9%	$55.5M+51.6%	$36.6M+38.9%	$26.4M-9.4%	$29.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$76.7M+173.4%	$28.0M+39.7%	$20.1M-13.5%	$23.2M+164.4%	$8.8M-27.8%	$12.2M
Current Liabilities	$76.7M+179.7%	$27.4M+43.3%	$19.1M-12.8%	$21.9M+150.0%	$8.8M-27.6%	$12.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$639.1M-27.4%	$880.3M+152.6%	$348.4M+139.8%	$145.3M-28.0%	$201.9M-17.4%	$244.3M
Retained Earnings	-$847.5M-73.7%	-$487.9M-29.1%	-$377.9M-29.4%	-$292.0M-30.9%	-$223.2M-32.7%	-$168.2M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$608.2M-15.0%	$715.7M-3.2%	$739.4M-10.7%	$827.9M-4.5%	$867.0M-4.5%	$908.3M-3.2%	$937.9M-0.9%	$946.8M
Current Assets	$608.2M-15.0%	$715.6M-3.1%	$738.7M-10.7%	$827.0M-4.5%	$866.0M-4.5%	$907.2M-3.1%	$936.6M-1.0%	$945.7M
Cash & Equivalents	$118.1M-28.8%	$165.8M+65.2%	$100.4M+196.3%	$33.9M-10.7%	$37.9M+42.2%	$26.7M-47.0%	$50.3M+14.6%	$43.9M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$106.3M+38.7%	$76.7M+190.6%	$26.4M-18.5%	$32.4M+61.3%	$20.1M-28.4%	$28.0M+6.1%	$26.4M+2.2%	$25.9M
Current Liabilities	$106.3M+38.7%	$76.7M+194.1%	$26.1M-18.5%	$32.0M+63.4%	$19.6M-28.6%	$27.4M+6.7%	$25.7M+2.4%	$25.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$501.9M-21.5%	$639.1M-10.4%	$713.0M-10.4%	$795.5M-6.1%	$846.9M-3.8%	$880.3M-3.4%	$911.4M-1.0%	$921.0M
Retained Earnings	-$1.0B-18.7%	-$847.5M-22.9%	-$689.9M-15.2%	-$599.1M-12.3%	-$533.5M-9.4%	-$487.9M-7.8%	-$452.5M-5.8%	-$427.6M

VKTX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$278.7M-217.4%	-$87.8M-19.6%	-$73.4M-51.6%	-$48.4M-1.7%	-$47.6M-118.5%	-$21.8M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$341.4M+161.7%	-$553.4M-209.0%	-$179.1M-427.1%	$54.8M+44.2%	$38.0M-8.7%	$41.6M
Financing Cash Flow	$76.4M-87.5%	$612.5M+125.7%	$271.4M+6418.8%	$4.2M-39.5%	$6.9M+624.2%	$950K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	$6.8M	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$114.0M-33.6%	-$85.3M+9.3%	-$94.0M-99.7%	-$47.1M+10.1%	-$52.3M-67.8%	-$31.2M-42.0%	-$22.0M+23.0%	-$28.5M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$54.2M-28.3%	$75.6M-52.7%	$160.0M+276.5%	$42.5M-32.8%	$63.2M+860.6%	$6.6M-74.6%	$25.9M+120.5%	-$126.1M
Financing Cash Flow	$12.1M-83.9%	$75.1M+15546.5%	$480K-5.3%	$507K+45.3%	$349K-65.1%	$1.0M-60.3%	$2.5M-13.2%	$2.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

VKTX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-56.3%-43.8pp	-12.5%+12.2pp	-24.6%+22.7pp	-47.4%-20.2pp	-27.2%-11.1pp	-16.2%
Return on Assets	-50.2%-38.1pp	-12.1%+11.2pp	-23.3%+17.6pp	-40.9%-14.8pp	-26.1%-10.7pp	-15.4%
Current Ratio	9.33-23.8	33.09+13.9	19.19+11.6	7.61-16.4	23.98+2.9	21.11
Debt-to-Equity	0.12+0.1	0.03-0.0	0.06-0.1	0.16+0.1	0.040.0	0.05
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-31.5%	N/A	-12.7%-4.5pp	-8.2%-2.8pp	-5.4%	N/A	-2.7%-0.3pp	-2.4%
Return on Assets	-26.0%	N/A	-12.3%-4.4pp	-7.9%-2.7pp	-5.3%	N/A	-2.7%-0.3pp	-2.4%
Current Ratio	5.72-3.6	9.33-19.0	28.34+2.5	25.86-18.4	44.25+11.2	33.09-3.4	36.47-1.2	37.69
Debt-to-Equity	0.21+0.1	0.12+0.1	0.040.0	0.04+0.0	0.020.0	0.030.0	0.030.0	0.03
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Immunovant Inc IMVT

$7.0B

Xenon Pharmaceut XENE

$5.2B

Crinetics Pharmaceuticals CRNX

$3.9B

Scholar Rock Holding SRRK

$5.7B

Soleno Therapeutics Inc SLNO

$2.8B

Frequently Asked Questions

What is Viking Therapeutics Inc's annual revenue?

Viking Therapeutics Inc (VKTX) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Viking Therapeutics Inc profitable?

No, Viking Therapeutics Inc (VKTX) reported a net income of -$359.6M in fiscal year 2025.

What is Viking Therapeutics Inc's return on equity (ROE)?

Viking Therapeutics Inc (VKTX) has a return on equity of -56.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Viking Therapeutics Inc's operating cash flow?

Viking Therapeutics Inc (VKTX) generated -$278.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Viking Therapeutics Inc's total assets?

Viking Therapeutics Inc (VKTX) had $715.7M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Viking Therapeutics Inc spend on research and development?

Viking Therapeutics Inc (VKTX) invested $345.0M in research and development during fiscal year 2025.

How many shares does Viking Therapeutics Inc have outstanding?

Viking Therapeutics Inc (VKTX) had 116M shares outstanding as of fiscal year 2025.

What is Viking Therapeutics Inc's current ratio?

Viking Therapeutics Inc (VKTX) had a current ratio of 9.33 as of fiscal year 2025, which is generally considered healthy.

What is Viking Therapeutics Inc's debt-to-equity ratio?

Viking Therapeutics Inc (VKTX) had a debt-to-equity ratio of 0.12 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Viking Therapeutics Inc's return on assets (ROA)?

Viking Therapeutics Inc (VKTX) had a return on assets of -50.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Viking Therapeutics Inc's cash runway?

Based on fiscal year 2025 data, Viking Therapeutics Inc (VKTX) had $165.8M in cash against an annual operating cash burn of $278.7M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Viking Therapeutics Inc's Piotroski F-Score?

Viking Therapeutics Inc (VKTX) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Viking Therapeutics Inc's earnings high quality?

Viking Therapeutics Inc (VKTX) has an earnings quality ratio of 0.77x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Viking Therapeutics Inc?

Viking Therapeutics Inc (VKTX) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.